Atom Bioworks

Atom Bioworks is pioneering the use of AI to overcome the limitations of traditional aptamer discovery, aiming to create a new generation of genetic medicines. The company has developed the proprietary AptaBLE AI platform, which accelerates aptamer design from months to days and outperforms structure-based tools like AlphaFold3 in binding prediction. Strategic recognitions include selection into the Google Cloud for AI Startup program and the NVIDIA Inception program, positioning the company at the intersection of computational biology and drug development.

AptaBLE (Aptamer Binding LanguagE): A transformer-based AI platform trained on proprietary protein-aptamer interaction data to design and optimize high-affinity, nuclease-resistant aptamers. AptLNP: A platform for creating aptamer-targeted lipid nanoparticles for cell-type specific delivery of genetic payloads beyond the liver.

Atom Bioworks competes with AI drug discovery companies (e.g., Recursion, Exscientia), aptamer-focused biotechs (e.g., Arrakis Therapeutics), and firms developing targeted LNPs (e.g., GenEdit). Its differentiation lies in its specialized AI model for nucleic acid-protein interactions and its integrated approach combining AI-designed aptamers with targeted delivery.